Valuation
- Market cap
- —
- Revenue TTM
- $0
- Net income TTM
- $0
- P/E (trailing)
- —
- P/E (forward)
- —
- Profit margin
- 0.00%
- Debt to equity
- —
Trading
- Volume
- 700
- Avg volume
- 2,974
- Day's range
- $0.06 – $0.06
- Shares out
- —
- Stochastic %K
- 4%
- Beta
- —
- Analysts
- —
- Price target
- —
Company profile
MindBio Therapeutics Corp., together with its subsidiaries, research, develops, and tests psychedelic substances as a potential treatment for the management of various mental health conditions in Australasia. The company also develops wearable devices to collect biometric data in mental health patients taking psychedelic medicines; and invests in research that forms the basis for developing novel and clinically prove...
Show more
MindBio Therapeutics Corp., together with its subsidiaries, research, develops, and tests psychedelic substances as a potential treatment for the management of various mental health conditions in Australasia. The company also develops wearable devices to collect biometric data in mental health patients taking psychedelic medicines; and invests in research that forms the basis for developing novel and clinically proven treatments for debilitating health conditions, such as depression, anxiety, PTSD, and chronic pain. MindBio Therapeutics Corp. was incorporated in 2021 and is headquartered in Vancouver, Canada.
- Industry
- Biotechnology
- Sector
- Healthcare
- Website
- https://www.mindbiotherapeutics.com
- Address
- 1055 West Georgia Street, 1500 Royal Centre P.O Box 11117, Vancouver, Canada
Latest news
No headlines yet.
